Rite Aid and EnvisionRx Collaborate to Improve Medication Adherence and Health Outcomes Through New Rx90 Program

Rx90 Offers Same Price for 90-day Prescriptions at Nearly 4,600 Rite Aid Pharmacies or via Home Delivery

New Program Leverages Tailored Communications, Plan Design and Clinical Support to Improve Patient Outcomes; Lower Benefit Costs for Health Plans and Employers

CAMP HILL, Pa. & TWINSBURG, Ohio--()--Rite Aid, one of the nation’s leading drugstore chains, and EnvisionRx, the pharmacy benefit management (PBM) division of EnvisionRxOptions and a wholly owned subsidiary of Rite Aid, announced today the availability of Rx90, a new program focused on improving medication adherence and health outcomes for consumers with chronic conditions.

Rx90, now available for EnvisionRx clients, gives consumers the option to fill their 90-day prescriptions at any of the nearly 4,600 Rite Aid pharmacy locations around the country. For the same price, consumers also have the option to have their medications delivered through EnvisionPharmacies’ mail service.

Other benefits of Rx90 include:

  • Integrated care and clinical support from Rite Aid pharmacists and EnvisionRx
  • Targeted, disease-specific communications
  • The largest 90-day retail maintenance medication network (over 12,000 total pharmacies)
  • Reduced copays that provide most members with 15-30 days of free coverage

In addition to providing consumers with improved pricing, more convenient options on how to fill their 90-day maintenance medications and additional clinical support, the collaboration between Rite Aid and EnvisionRx helps to address rising health care costs. According to a 2014 Towers Watson study of employer provided health care, the consumer’s share of health care costs, including premiums and out-of-pocket costs, has grown from 34.4% in 2011 to 37% in 2014, an average increase of about $100 more a month.

“Rite Aid is excited to work with EnvisionRx to bring an innovative pharmacy solution for consumers, health plans and employers to market,” said Jocelyn Konrad, Rite Aid executive vice president of pharmacy. “Rx90 is a great example of how our pharmacies and PBMs can collaborate to achieve our shared goal of improving the patient experience and care, while reducing and managing healthcare costs.”

Using client-specific data and its own research, EnvisionRx is also able to provide health plans and employers with recommendations on customizing their benefit design, communications, and clinical strategies to meet their individual needs. Rx90 will help plan sponsors better control drug spend and reduce costly medical expenses associated with increased visits to physicians and emergency rooms, as well as extended hospitalizations.

“In today’s market, plan sponsors and their members need a PBM that truly provides more flexible, affordable options to control the costs of chronic care. Rx90 and our technology platform give plan sponsors another way to customize their prescription drug benefit plan and put actionable, cost saving information in the hands of their members,” said Frank Sheehy, EnvisionRxOptions CEO.

Rite Aid Corporation (NYSE: RAD) is one of the nation's leading drugstore chains with nearly 4,600 stores in 31 states and the District of Columbia and fiscal 2016 annual revenues of $30.7 billion. Information about Rite Aid, including corporate background and press releases, is available through the company's website at www.riteaid.com.

EnvisionRx is a division of EnvisionRxOptions, a health care company with a visibly different approach to managing pharmacy benefits. As a full service provider, Envision leverages its core PBM services including Mail, Specialty and Compounding Pharmacies; Part D Medicare insurance plans; and cash savings programs, to help employers and health plans of all sizes provide more affordable and effective prescription drug coverage for their members. Headquartered in Twinsburg, Ohio, EnvisionRxOptions is a wholly owned subsidiary of Rite Aid. For more information, visit www.envisionrxoptions.com.

Contacts

Rite Aid
INVESTORS:
Matt Schroeder, 717-214-8867
investor@riteaid.com
or
MEDIA:
Ashley Flower, 717-975-5718
or
EnvisionRxOptions
MEDIA:
Bobby Creek, 813-690-8503
bcreek@envisionrx.com

Contacts

Rite Aid
INVESTORS:
Matt Schroeder, 717-214-8867
investor@riteaid.com
or
MEDIA:
Ashley Flower, 717-975-5718
or
EnvisionRxOptions
MEDIA:
Bobby Creek, 813-690-8503
bcreek@envisionrx.com